Transthyretin Amyloidosis With Polyneuropathy

1

Review clinical trials related to Transthyretin Amyloidosis With Polyneuropathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic impairment, as well as to assess long-term safety among all new users of eplontersen; all are areas of missing information Primary objectives are: 1. To describe demographic and clinical characteristics of patients at eplontersen initiation, including the prevalence of prior liver transplant (overall and by reason for liver transplant), and the prevalence of severe hepatic impairment; and to describe patients in these subgroups (prior liver transplant, severe hepatic impairment). 2. To describe long-term safety in patients who initiate eplontersen treatment, including onset of new clinical events, abnormal laboratory values and serious adverse events.

Participants needed: 320
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: AstraZenecaUpdated: Jun 17, 2026
Eligibility criteria

D8450R00003 participants who consented to have their data used for future relate... [+1]

Patients with exposure to eplontersen more than 1-year prior to enrolment into D... [+1]